Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature

Терапевтический архив

N G GABEEVA¹  D A KOROLEVA¹  E E ZVONKOV¹  M M CHUKAVINA¹  T N OBUKHOVA¹  A M KOVRIGINA¹ 

[1] National Research Center for Hematology, Russian Federation;

关键词: dlbcl;    gcb- dlbcl;    non-gcb- dlbcl;    auto-hematopoietic stem cell transplantation;    lenalidomide;   

DOI  :  10.26442/terarkh201890796-101

来源: DOAJ

【 摘 要 】

Diffuse large B-cell lymphoma is categorized by gene expression profiling into germinal center (GCB) and activated B-cell (ABC) subtype, also referred to as non-germinal center B-cell (non-GCB) by immunohistochemistry. ABC DLBCL is characterized by NF-κB pathway activation and high expression of IRF4/MUM1, a key transcription factor in B cell differentiation. Patients with ABC DLBCL have a significantly worse outcome when treated with standard chemotherapy (R-CHOP). Lenalidomide have shown activity in the ABC-DLBCL in combination with R-CHOP. But about 40% of patients remain resistant. We present the experience of treatment of a patient with generalized non-GCB-DLBCL using the intensive protocol R-mNHL-BFM-90 with lenalidomide.

【 授权许可】

Unknown